Alexander Fullman

Cooley advised Lexeo Therapeutics, a clinical-stage gene therapy company advancing gene therapy candidates for genetically defined cardiovascular diseases and a genetically defined subgroup of Alzheimer’s disease, on its approximately $100 million initial public offering.

Cooley advised CinCor Pharma, a clinical-stage biopharmaceutical company, on its definitive agreement to be acquired by AstraZeneca. M&A partners Rama Padmanabhan and Rowook Park and corporate partners Div Gupta and Sarah Sellers led the Cooley team.

Cooley advised CinCor Pharma on its upsized $212 million initial public offering of 13,290,813 shares of common stock, which included a partial exercise of the underwriter’s option to purchase additional shares of common stock. CinCor, whose shares now trade on the Nasdaq Global Market under the symbol CINC, is a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CinCor’s IPO was one of the first IPOs of 2022. Partners Ryan Sansom, Div Gupta and Courtney Thorne led the Cooley team.